Oruka Therapeutics Overview
Oruka Therapeutics Target Price
Analysts' 12-month price predictions for ORKA.
Get informed when a big investor buys or sells
+ FollowShare Price
$85.21
Average Target Price
$134.91
58.3% upside
58.3% upside11 analysts in the last 4 months
High: $200 | Low: $73
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-07-01 | UBS | $130 | 52.6% upside |  |
| 2026-06-02 | Piper SandlerYasmeen Rahimi | $180 | 111.2% upside | |
| 2026-04-30 | Leerink Partners | $120 | 40.8% upside | |
| 2026-04-29 | H.C. Wainwright | $120 | 40.8% upside | |
| 2026-04-28 | UBS | $100 | 17.4% upside | |
| 2026-04-27 | BTIG | $151 | 77.2% upside | |
| 2026-04-27 | Wedbush | $165 | 93.6% upside | |
| 2026-04-27 | BarclaysEtzer Darout | $160 | 87.8% upside | |
| 2026-04-27 | Guggenheim | $200 | 134.7% upside | |
| 2026-04-15 | Wedbush | $85 |  0.2% downside | |
| 2026-03-13 | BTIGJulian Harrison | $73 | 14.3% downside | |
| 2026-01-13 | Wedbush | $45 | 47.2% downside | |
| 2026-01-07 | UBSMichael Yee | $50 | 41.3% downside | |
| 2025-12-18 | Piper Sandler | $75 | 12% downside | |
| 2025-10-27 | Guggenheim | $60 | 29.6% downside | |
| 2025-10-27 | H.C. WainwrightMitchell Kapoor | $40 | 53.1% downside | |
| 2025-10-13 | Barclays | $48 | 43.7% downside | |
| 2025-02-04 | Wolfe ResearchAndy Chen | $20 | 76.5% downside | |
| 2024-09-12 | JefferiesMichael Yee | $40 | 53.1% downside | |
| 2024-09-04 | WedbushDavid Nierengarten | $40 | 53.1% downside | |